Prima BioMed Limited
(ASX:PRR) has raised $1.55 million from specialist healthcare investor Nyenburgh Investment Partners.
The immune-oncology company announced the raising was completed by a placement of shares at $0.05 per share to Nyenburgh Investment Partners.
The capital raised from the private placement will be used to fund Prima’s IMP321 clinical trial program and provide additional working capital.
In May of this year Prima BioMed announced a $15 million investment from US specialist healthcare investor Ridgeback Capital Investments. The company also raised $10 million via a Share Purchase Plan in June.
Prima BioMed reported a net loss of $32.15 million at 30 June 2015.
